These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4740303)

  • 1. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.
    Greenblatt DJ; Koch-Weser J
    JAMA; 1973 Jul; 225(1):40-3. PubMed ID: 4740303
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diuretics in cirrhosis. Accidents. Indications].
    Andrieu J; Lesueur G
    Presse Med (1893); 1969 Mar; 77(16):575-8. PubMed ID: 5783378
    [No Abstract]   [Full Text] [Related]  

  • 3. [Urea and spironolactone therapy].
    Schwarzbach W; Bunzl W
    Munch Med Wochenschr; 1973 Jan; 115(3):76-80. PubMed ID: 4739290
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.
    Abbas Z; Mumtaz K; Salam A; Jafri W
    J Coll Physicians Surg Pak; 2003 Jul; 13(7):382-4. PubMed ID: 12887837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperkalemia during spironolactone use in patients with decompensated heart failure.
    Lima MV; Ochiai ME; Cardoso JN; Morgado PC; Munhoz RT; Barretto AC
    Arq Bras Cardiol; 2008 Sep; 91(3):177-82, 194-9. PubMed ID: 18853060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
    Berry C; McMurray JJ
    Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone and ammonium and potassium chloride.
    Mashford ML; Robertson MB
    Br Med J; 1972 Nov; 4(5835):298-9. PubMed ID: 5083905
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current diuretic treatment. Physiopathologic basis].
    Fournier A
    Presse Med (1893); 1970 Apr; 78(20):945-54. PubMed ID: 4909751
    [No Abstract]   [Full Text] [Related]  

  • 12. Hyperkalemic intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosis.
    Radó JP; Marosi J; Takó J; Dévényi I
    Am Heart J; 1968 Sep; 76(3):393-8. PubMed ID: 4951338
    [No Abstract]   [Full Text] [Related]  

  • 13. Spironolactone in patients with heart failure.
    Vanpee D; Swine C
    N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636753
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of spironolactone on blood pressure in subjects with resistant hypertension.
    Chapman N; Dobson J; Wilson S; Dahlöf B; Sever PS; Wedel H; Poulter NR;
    Hypertension; 2007 Apr; 49(4):839-45. PubMed ID: 17309946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complications of diuretic therapy in patients with cirrhosis.
    Sherlock S; Walker JG; Senewiratne B; Scott A
    Ann N Y Acad Sci; 1966 Nov; 139(2):497-505. PubMed ID: 5230290
    [No Abstract]   [Full Text] [Related]  

  • 16. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potassium supplements and diuretics.
    Vesin P
    Lancet; 1972 Dec; 2(7789):1262-3. PubMed ID: 4117763
    [No Abstract]   [Full Text] [Related]  

  • 19. Life-threatening, preventable hyperkalemia in a nursing home resident: case report and literature review.
    Dharmarajan TS; Nguyen T; Russell RO
    J Am Med Dir Assoc; 2005; 6(6):400-5. PubMed ID: 16286062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Male gynecomastia.
    Haynes BA; Mookadam F
    Mayo Clin Proc; 2009 Aug; 84(8):672. PubMed ID: 19648382
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.